Achilles Therapeutics (ACHL)
Achilles Therapeutics Statistics
Share Statistics
Achilles Therapeutics has 41.1M shares outstanding. The number of shares has increased by 0.03% in one year.
Shares Outstanding | 41.1M |
Shares Change (YoY) | 0.03% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 60.1% |
Shares Floating | 20.06M |
Failed to Deliver (FTD) Shares | 7.74K |
FTD / Avg. Volume | 0.62% |
Short Selling Information
The latest short interest is 159.25K, so 0.39% of the outstanding shares have been sold short.
Short Interest | 159.25K |
Short % of Shares Out | 0.39% |
Short % of Float | 0.42% |
Short Ratio (days to cover) | 1.69 |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is -9.46. Achilles Therapeutics's PEG ratio is undefined.
PE Ratio | undefined |
Forward PE | -9.46 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | 0.25 |
P/FCF Ratio | undefined |
PEG Ratio | undefined |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Achilles Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.57, with a Debt / Equity ratio of undefined.
Current Ratio | 8.57 |
Quick Ratio | 8.57 |
Debt / Equity | undefined |
Debt / EBITDA | - |
Debt / FCF | - |
Interest Coverage | undefined |
Financial Efficiency
Return on Equity is -0.49% and Return on Invested Capital is -51.56%.
Return on Equity | -0.49% |
Return on Assets | -0.43% |
Return on Invested Capital | -51.56% |
Revenue Per Employee | $0 |
Profits Per Employee | $-341.5K |
Employee Count | 204 |
Asset Turnover | 0 |
Inventory Turnover | 4.73M |
Taxes
Income Tax | 491K |
Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by 18.4% in the last 52 weeks. The beta is 1.25, so Achilles Therapeutics's price volatility has been higher than the market average.
Beta | 1.25 |
52-Week Price Change | 18.4% |
50-Day Moving Average | 1.32 |
200-Day Moving Average | 1.02 |
Relative Strength Index (RSI) | 76.37 |
Average Volume (20 Days) | 1.25M |
Income Statement
Revenue | n/a |
Gross Profit | -4.73M |
Operating Income | -75.25M |
Net Income | -69.67M |
EBITDA | -70.44M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.74 |
Balance Sheet
The company has 131.54M in cash and 4.62M in debt, giving a net cash position of 126.92M.
Cash & Cash Equivalents | 131.54M |
Total Debt | 4.62M |
Net Cash | 126.92M |
Retained Earnings | -259.95M |
Total Assets | 122.68M |
Working Capital | 93.16M |
Cash Flow
In the last 12 months, operating cash flow was -48.45M and capital expenditures -1.1M, giving a free cash flow of -49.55M.
Operating Cash Flow | -48.45M |
Capital Expenditures | -1.1M |
Free Cash Flow | -49.55M |
FCF Per Share | -1.24 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ACHL does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -117.57% |
FCF Yield | -81.46% |
Analyst Forecast
The average price target for ACHL is $4, which is 170.3% higher than the current price. The consensus rating is "Hold".
Price Target | $4 |
Price Target Difference | 170.3% |
Analyst Consensus | Hold |
Analyst Count | 2 |
Scores
Altman Z-Score | -2.67 |
Piotroski F-Score | 1 |